Kansas City Star

Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S.

In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...
Drug Store News

Biocon Biologics, Civica collaborate to expand insulin Aspart access

Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...
Morningstar

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...
JD Supra

Biocon Regulatory Approval Updates in the U.S. and Europe: Insulin Aspart and Denosumab

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has approved KIRSTY (insulin aspart-xjhz injection), 100 units ...
Los Angeles Magazine

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients

Members of the editorial and news staff of the Los Angeles magazine and the Engine Vision Media Network were not involved in the creation of this content. A new agreement between Biocon Biologics Ltd.
Morningstar

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...
BioWorld

Biocon wins first FDA interchangeable label of Novolog biosimilar

The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo Nordisk A/S’ Novolog (insulin aspart), a ...